home / stock / surf / surf news

SURF News and Press, Surface Oncology Inc. From 12/02/21

Stock Information
Company Name: Surface Oncology Inc.
Stock Symbol: SURF
Market: NASDAQ
Website: surfaceoncology.com
Menu
SURF SURF Quote SURF Short SURF News SURF Articles SURF Message Board
Get SURF Alerts

News, Short Squeeze, Breakout and More Instantly...
SURF - Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a poster presentation sharing new clinical data from ...
SURF - Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG

CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has clear...

SURF - Cathie Wood Goes Bargain Shopping -- 3 Troubled Stocks She Just Bought

The week of Thanksgiving in the U.S. is supposed to be a slow one but nobody told the internet's favorite investor. Cathie Wood scooped up dozens of her favorite stocks for Ark Invest's exchange-traded funds ( ETFs ) last week. This has been a tough year for tech stocks across the b...

SURF - Preclinical Data Supporting Therapeutic Potential of Surface Oncology's Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that two scientific posters sharing updated preclinical da...
SURF - Surface Oncology to Participate in the 2021 Annual Cowen IO Next Summit

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will partici...

SURF - Surface Oncology EPS misses by $0.04, beats on revenue

Surface Oncology (NASDAQ:SURF): Q3 GAAP EPS of -$0.44 misses by $0.04. Revenue of $392M beats by $389.54M. Press Release For further details see: Surface Oncology EPS misses by $0.04, beats on revenue

SURF - Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results for the third quarter 2021, and provided ...
SURF - Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that scientific posters sharing preclinical data will be prese...

SURF - Surface Oncology Announces New Randomized Phase 2 Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche

CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced details about its plan to initiate a randomized Phase 2 cl...

SURF - Why AstraZeneca and Surface Oncology Rose Today

AstraZeneca (NASDAQ: AZN) and Surface Oncology (NASDAQ: SURF) shares both traded up on Monday, bucking the heavily bearish trend of the overall stock market. AstraZeneca closed the day more than 5% higher on the back of positive news about its cancer drug, while Surface Onco...
Previous 10 Next 10